EDX Medical Group plc (AIM: EDX), the Cambridge-based developer of digital diagnostic products and services for early disease detection, has disclosed that Chief Executive Officer Dr Michael Hudson purchased 75,000 ordinary shares on 4 November 2026 at an average price of 6.83 pence per share via open market trading. Separately, Sebastian Hudson, a person closely associated with the CEO, purchased 25,000 shares on the same date at an average price of 6.75 pence per share. Following these transactions, Dr Hudson controls 20,750,000 ordinary shares, representing 4.81% of EDX Medical's issued share capital. The purchases were made on the London Stock Exchange's AIM market and disclosed under UK Market Abuse Regulation obligations.

Key Points

  • EDX Medical Group plc (AIM: EDX), Cambridge-based digital diagnostics developer
  • CEO Dr Michael Hudson purchased 75,000 ordinary shares at an average price of 6.83p on 4 November 2026
  • Person closely associated with the CEO, Sebastian Hudson, purchased 25,000 shares at an average of 6.75p; Sebastian Hudson now holds 75,000 ordinary shares in the Company
  • Dr Hudson's combined controlled holding stands at 20,750,000 shares, equal to 4.81% of issued share capital

CEO Dr Michael Hudson's 75,000-Share Purchase Broken Down Across Three Price Points

According to the regulatory notification, Dr Hudson's 75,000-share acquisition on 4 November 2026 was executed across three tranches: 35,000 shares at 6.5 pence, 5,000 shares at 6.99 pence, and 35,000 shares at 7.0 pence, producing the stated aggregate average price of 6.83 pence per share. The transaction was conducted on XLON:AIMX, the AIM market segment of the London Stock Exchange. The announcement was made in accordance with Article 19(1) of the EU Market Abuse Regulation as incorporated into UK law through the European Union (Withdrawal) Act 2018, and the company's directors accept responsibility for the disclosure's contents.

Sebastian Hudson Adds 25,000 Shares, Bringing His Total Holding to 75,000 Ordinary Shares

Sebastian Hudson, identified in the announcement as a person closely associated with Dr Michael Hudson, purchased 25,000 ordinary shares on 4 November 2026 in two tranches: 10,000 shares at 6.5 pence and 15,000 shares at 7.0 pence, resulting in an average price of 6.75 pence per share. Following this acquisition, Sebastian Hudson holds a total of 75,000 ordinary shares in EDX Medical Group. Like the CEO's purchase, this transaction was executed on XLON:AIMX and disclosed as an initial notification under UK market abuse reporting requirements.

EDX Medical's Cambridge Operations and Diagnostic Portfolio Provide Context for the Director Activity

EDX Medical Group, co-founded by Professor Sir Christopher Evans OBE and Dr Hudson, develops and supplies digital diagnostic products and services aimed at improving early detection and treatment of major diseases. The company operates its own facilities in Cambridge, UK, and maintains strategic partnerships with organisations including Thermo Fisher EMEA Ltd, a global life sciences solutions provider. EDX Medical supplies doctors, hospitals, and insurers with access to a portfolio of clinical diagnostics products and services. Canaccord Genuity Limited acts as the company's Nominated Adviser and Broker. Investors may watch for further operational updates as the company pursues its early-detection diagnostics strategy.